argenx SE American Depositary Shares (ARGX) Valuation
Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA...
argenx SE American Depositary Shares (ARGX) currently trades at a P/E ratio of 53.59 (historical range: 42.46–53.80, median: 44.77), placing it at the 93th percentile — expensive relative to its history, P/S ratio of 16.30 (range: 12.91–16.36, 93th percentile — expensive relative to its history), EV/EBITDA of 61.54 (range: 47.89–61.79, 93th percentile).
argenx SE American Depositary Shares appears overvalued relative to its own historical valuation range, trading at elevated multiples across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 53.59 | 42.46 | 44.77 | 53.80 | 93th | expensive relative to its history |
| P/S Ratio | 16.30 | 12.91 | 13.62 | 16.36 | 93th | expensive relative to its history |
| EV/EBITDA | 61.54 | 47.89 | 50.72 | 61.79 | 93th | expensive relative to its history |